BCR-ABL, KIT, and PDGFRA Kinase Group (BCR-ABL/KIT/PDGFRA)

This entry represents a conceptual grouping of three distinct receptor tyrosine kinases: BCR-ABL, KIT, and PDGFRA. While each is a unique and important therapeutic target, they are frequently discussed together due to their shared involvement in various hematologic malignancies (e.g., CML, AML, MPN) and gastrointestinal stromal tumors (GIST), and because some tyrosine kinase inhibitors (e.g., Imatinib, Dasatinib) target more than one of these. BCR-ABL is a fusion protein forming the Philadelphia chromosome, a primary driver in CML and some ALL. KIT and PDGFRA are transmembrane receptor tyrosine kinases often activated by mutations in GIST and other myeloproliferative disorders. Listing them together as a single canonical target is technically imprecise, as each has distinct molecular characteristics, biological functions, and specific disease contexts, despite overlapping clinical relevance and therapeutic approaches. Pathogenic activation of all three contributes to oncogenesis and they are validated therapeutic targets.

Other names

Philadelphia chromosome (Ph)BCR-ABL1Ph+ fusion proteinCD117SCFRc-KitCD140aPDGFR-alphaOncogenic Kinase GroupHematologic/GIST Kinase Targets

These drugs primarily act as tyrosine kinase inhibitors, often through ATP-competitive inhibition, to block the aberrant signaling pathways driven by these oncogenic kinases. Mechanisms include inhibition of ATP-binding, allosteric inhibition, induction of apoptosis, reduction of oncogenic signaling, inhibition of cell proliferation, and blockade of growth factor signaling.